SEARCH

SEARCH BY CITATION

Keywords:

  • acral erythema;
  • acral erythrodysesthesia;
  • adverse reaction;
  • cutaneous reaction;
  • drug reaction;
  • hand-foot syndrome;
  • human keratinocyte growth factor;
  • palifermin;
  • palmar plantar syndrome;
  • toxic erythema of palms and soles

ABSTRACT

The recombinant human keratinocyte growth factor, palifermin, offers a potential means of reducing or preventing mucositis in patient undergoing intensive cancer treatments. This case report details the development of acral erythrodysaesthesia in one patient who underwent palifermin treatment prior to high-intensity re-induction chemotherapy for acute myeloid leukaemia.